“Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer” (2021), by Kai Li et al. Immunology and Microbiology research paper. Original abstract below, unchanged. A free PDF is available.

Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

Kai Li, Houhui Shi, Benxia Zhang et al. · October 7, 2021 · Immunology and Microbiology

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature myeloid cells with immunosuppressive effects, which undergo massive expansion during tumor progression. These cells not only support immune escape directly but also promote tumor invasion via various non-immunological activities. Besides, this group of cells are proved to impair the efficiency of current antitumor strategies such as chemotherapy, radiotherapy, and immunotherapy. Therefore, MDSCs are considered as potential therapeutic targets for cancer therapy. Treatment strategies targeting MDSCs have shown promising outcomes in both preclinical studies and clinical trials when administrated alone, or in combination with other anticancer therapies. In this review, we shed new light on recent advances in the biological characteristics and immunosuppressive functions of MDSCs. We also hope to propose an overview of current MDSCs-targeting therapies so as to provide new ideas for cancer treatment.

Free PDF DOI: 10.1038/s41392-021-00670-9